Overview
| abca1-protein | |
|---|---|
| Symbol | ABCA1 |
| Full Name | abca1-protein |
| Type | Protein |
| UniProt | Search UniProt |
| Associated Diseases | AD, ALS, AMI, ARM, ATHEROSCLEROSIS |
| KG Connections | 378 edges |
ABCA1 (ATP-binding cassette transporter A1) is a member of the ABC transporter family that plays a critical role in cholesterol efflux and lipid homeostasis throughout the body, including the central nervous system1Human ATP-binding cassette (ABC) transporter familyOpen reference. In the brain, ABCA1 is essential for the lipidation of apolipoprotein E (ApoE) secreted by astrocytes, a process critical for amyloid-beta clearance and neuronal function2Role of ABCA1 and ABCG1 transporters in cholesterol efflux and Alzheimer's diseaseOpen reference.
ABCA1 is expressed in many tissues, including liver, macrophages, microglia, astrocytes, and neurons. Its dysfunction has been implicated in Alzheimer’s disease, Parkinson’s disease, and atherosclerosis3ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted ApoEOpen reference. The protein functions as a key regulator of reverse cholesterol transport and is essential for the formation of high-density lipoprotein (HDL) particles.
Structure
ABCA1 has the typical architecture of ABC transporters4Purification and ATPase activity of human ABCA1Open reference:
Transmembrane Domains
-
Two transmembrane domains (TMDs): Each containing 6 transmembrane helices
-
Extracellular loops: Form the substrate entry portal for lipids
-
Intracellular loops: Connect TMDs and contain regulatory elements
Nucleotide-Binding Domains
-
Two nucleotide-binding domains (NBDs): Located at the cytoplasmic face
-
Walker A motif: Binds ATP phosphate groups
-
Walker B motif: Coordinates magnesium ion
-
ABC signature (C-loop): Contains the conserved LSGGQ motif
-
H-loop (switch region): Contains the catalytic histidine for ATP hydrolysis
Structural Features
-
N-terminal extracellular domain: Unique to the ABCA subfamily
-
Coupling helices: Connect TMDs to NBDs for conformational transmission
-
Dimerization: Forms functional homodimers in the plasma membrane
Comparison with Other ABC Transporters
ABCA1 shares structural homology with other ABCA family members:
-
ABCA4: Retinal transporter (visual cycle)
-
ABCA2: Brain-expressed, associated with AD risk
-
ABCA3: Lung surfactant homeostasis
-
ABCA7: Cholesterol efflux, linked to AD
Normal Function
Cholesterol Efflux
ABCA1 is the central mediator of cellular cholesterol efflux
-
Transfers cholesterol and phospholipids to apolipoproteins (ApoA-I, ApoE)
-
Mediates the first step in reverse cholesterol transport
-
Prevents foam cell formation in atherosclerosis
HDL Particle Formation
ABCA1 is essential for nascent HDL particle formation:
-
Binds ApoA-I via the extracellular loops
-
Transfers lipids to form pre-beta HDL particles
-
Initiates the HDL maturation pathway
Cellular Lipid Homeostasis
ABCA1 maintains cellular lipid balance:
-
Prevents cholesterol accumulation in cells
-
Regulates membrane lipid composition
-
Supports cellular stress responses
Phagocytosis in Microglia
ABCA1 modulates microglial function5ABCA1 in microglia and neuroinflammationOpen reference:
-
Supports phagocytosis of cellular debris
-
Modulates inflammatory responses
-
Essential for amyloid clearance
Role in Neurodegeneration
Alzheimer’s Disease
ABCA1 plays a critical role in AD pathogenesis through multiple mechanisms6ABCA1 and Alzheimer's disease: mechanisms and therapeutic potentialOpen reference:
ApoE Lipidation
-
ABCA1 is required for proper lipidation of astrocyte-secreted ApoE3ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted ApoEOpen reference
-
Lipidated ApoE is more effective at Aβ clearance
-
ABCA1 deficiency leads to poorly lipidated ApoE particles
-
Reduced Aβ clearance across the blood-brain barrier
Amyloid Clearance
-
ABCA1 deficiency promotes amyloid pathology in AD mouse models7ATP-binding cassette transporter A1 deficiency promotes amyloid pathology in Alzheimer's diseaseOpen reference
-
Lipidated ApoE-Aβ complexes are cleared more efficiently
-
ABCA1 regulates Aβ degradation by microglia
-
Astrocyte ABCA1 supports neuronal Aβ clearance
Genetic Association
-
ABCA1 polymorphisms associated with AD risk
-
Variants affect ApoE lipidation capacity
-
Some variants protective, others risk-increasing
Therapeutic Implications
-
LXR agonists increase ABCA1 expression8Liver X receptors as integrators of metabolic and inflammatory signalingOpen reference
-
ABCA1 upregulation reduces amyloid pathology9Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficitsOpen reference
-
Must balance peripheral and CNS effects
Parkinson’s Disease
ABCA1 is implicated in PD through lipid metabolism alterations:
-
Altered cholesterol metabolism in PD brains
-
ABCA1 variants may modify PD risk
-
Role in dopaminergic neuron survival
-
Connections to α-synuclein aggregation
Neuroinflammation
ABCA1 modulates neuroinflammatory responses2Role of ABCA1 and ABCG1 transporters in cholesterol efflux and Alzheimer's diseaseOpen reference0:
-
Regulates microglia cholesterol homeostasis
-
Modulates pro-inflammatory cytokine production
-
ABCA1 deficiency increases neuroinflammation
-
Therapeutic potential for inflammatory conditions
Other Neurodegenerative Conditions
-
Multiple Sclerosis: Role in myelin maintenance
-
Huntington’s Disease: Altered cholesterol homeostasis
-
Amyotrophic Lateral Sclerosis: Lipid metabolism changes
Therapeutic Targeting
LXR Agonists
Liver X receptor (LXR) agonists are potent ABCA1 inducers2Role of ABCA1 and ABCG1 transporters in cholesterol efflux and Alzheimer's diseaseOpen reference1:
-
TO901317: Increases ABCA1 expression in vitro and in vivo
-
GW3965: Synthetic LXR agonist
-
Clinical challenge: Peripheral side effects (lipogenesis)
Clinical Trial Results
-
LXR agonists showed promise in AD mouse models2Role of ABCA1 and ABCG1 transporters in cholesterol efflux and Alzheimer's diseaseOpen reference2
-
Limited by increased triglyceride levels
-
CNS-selective compounds in development
Gene Therapy
-
AAV-mediated ABCA1 delivery to CNS
-
Targeted expression in astrocytes
-
Potential for sustainable therapeutic benefit
Small Molecule Activators
-
Direct ABCA1 activators in development
-
Structure-activity relationship studies
-
Selective CNS-active compounds
Combination Approaches
-
LXR agonists with other therapeutics
-
ABCA1 upregulation plus Aβ immunotherapy
-
ApoE-directed therapies
Key Publications
-
Takahashi K, et al., Purification and ATPase activity of human ABCA1 (2006)
-
Volpicella M, et al., ATP-binding cassette transporters in neurodegeneration (2020)
-
Vasiliou V, et al., Human ATP-binding cassette (ABC) transporter family (2009)
-
Wahrle SE, et al., ABCA1 is required for normal central nervous system ApoE levels (2005)
-
Fitz NF, et al., Liver X receptor agonist treatment ameliorates amyloid pathology (2010)
-
Hu Y, et al., ABCA1 deficiency promotes amyloid pathology in Alzheimer’s disease (2020)
-
Vitali C, et al., ABCA1 and cholesterol efflux in the brain (2014)
-
Yvan-Charvet L, et al., ABCA1, ABCG1, and cholesterol homeostasis in macrophages (2010)
-
Karinasinska JM, et al., ABCA1 deficiency and apoE metabolism in neurons (2013)
-
Pincher A, et al., ABCA1 in microglia and neuroinflammation (2020)
-
Liu Q, et al., ABCA1 and Alzheimer’s disease: mechanisms and therapeutic potential (2019)
-
Chen J, et al., ABCA1 and cholesterol efflux in neurons (2018)
Cross-Links
-
ABCA1 Gene - Gene page
-
ApoE Protein - Key substrate
-
Cholesterol Metabolism - Pathway
-
HDL Particle - Product
-
Alzheimer’s Disease - Disease
-
Parkinson’s Disease - Disease
-
Microglia - Cell type
References
- Human ATP-binding cassette (ABC) transporter family
- Role of ABCA1 and ABCG1 transporters in cholesterol efflux and Alzheimer's disease
- ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted ApoE
- Purification and ATPase activity of human ABCA1
- ABCA1 in microglia and neuroinflammation
- ABCA1 and Alzheimer's disease: mechanisms and therapeutic potential
- ATP-binding cassette transporter A1 deficiency promotes amyloid pathology in Alzheimer's disease
- Liver X receptors as integrators of metabolic and inflammatory signaling
- Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits
Sister wikis (recently updated · no domain on this page)
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- test
- JGBO-I27: Top 10 GBO Questions for Prioritization
- JGBO-I27: Top 10 GBO Questions for Prioritization
- Design Brief: Beta-test Evaluation Protocol for SciDEX v2 Design Trajectories
- Andy — Showcase Findings (auto-curated)
- Kris — Showcase Findings (auto-curated)
Recent activity here
No recent events touching this page.